Profusa, Inc. (PFSA)
| Market Cap | 323.60K -95.8% |
| Revenue (ttm) | n/a |
| Net Income | -42.97M |
| EPS | -1,983.75 |
| Shares Out | 605.65K |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 249,972 |
| Open | 0.5180 |
| Previous Close | 0.5698 |
| Day's Range | 0.5100 - 0.5511 |
| 52-Week Range | 0.5100 - 1,593.7540 |
| Beta | 0.59 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings | Nov 23, 2026 |
About PFSA
Profusa, Inc., a digital health technology company, develops bioengineered sensors for body to detect and continuously transmit clinical-grade data for personal and medical use in the United States. It offers the Lumee Oxygen Platform to monitor compromised tissue for peripheral artery disease, chronic wounds, and reconstructive surgery. The company researches and develops the Lumee Glucose Platform which is designed to monitor glucose levels in interstitial fluid. Profusa, Inc. is based in Berkeley, California.
Financial Performance
Financial StatementsNews
Profusa receives ISO 13485:2016 certificate from GMED
Profusa (PFSA)announced that it has received its ISO 13485:2016 certificate from GMED, a notified body designated under the European Union Medical Device Regulation. The certificate covers the design,...
Profusa Receives ISO 13485:2016 Certificate from GMED
Providing a Foundational Quality Management System (QMS) for Commercialization
Why Is Penny Stock Profusa (PFSA) Up Today?
Profusa stock rocketed 71.33% on Thursday following a press release that covered an update for the company’s ISO 13485, a quality standard for medical devices.
Profusa announces progress towards Lumee oxygen platform CE mark
Profusa (PFSA)announced that the Company has received a positive decision from GMED regarding certification of its quality management system to ISO 13485. GMED is a notified body designated under the…
Profusa Announces Significant Progress Towards Lumee® Oxygen Platform CE Mark with ISO 13485 Certification Expected in Early October
BERKELEY, CA, Sept. 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensor technologies today announced that the Company has received ...
Profusa regains Nasdaq compliance
Profusa (PFSA)announced that on September 9, 2026, the company received a letter from The Nasdaq Stock Market confirming that the company has demonstrated compliance with Nasdaq Listing Rule 5550(a)(2...
Profusa, Inc. Receives Nasdaq Compliance Determination
Berkeley, CA, Sept. 15, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced today that on September 9, 2026, the Company received a letter (the “Compliance Determination Le...
Profusa regains compliance with Nasdaq
Profusa (PFSA)announced that it has received a letter from Nasdaq stating that following the effectiveness of the company’s 1-for-4 reverse stock split, the company had less than the 500,000 publicly…
Profusa, Inc. Announces Compliance with Nasdaq Publicly Held Shares Requirement
Berkeley, CA, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA) (the “Company”) announced that it has received a letter (the “Notice”) from the Listing Qualifications Department of The Na...
Profusa Inc trading halted, volatility trading pause
09:36 EDT Profusa (PFSA)Inc trading halted, volatility trading pause
Profusa Inc trading halted, volatility trading pause
09:33 EDT Profusa (PFSA)Inc trading halted, volatility trading pause
Profusa Announces Q2 2026 Financial Results and Progress on the Option Agreement Conditions to Close with G3 Vision Labs, a Commercial Stage Diagnostics Company
Debt and liabilities holders have executed $10.7 million of Series A Convertible Exchange Agreements; of which $4.57 million was converted into Series A Convertible Preferred Stock
Profusa announces 1-for-4 reverse stock split
Profusa (PFSA)announced that it led an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to elect a one-for-four reverse…
Profusa Inc trading halted, news pending
19:50 EDT Profusa (PFSA)Inc trading halted, news pending
Profusa Announces 1-for-4 Reverse Stock Split
BERKELEY, California, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology pla...
Profusa Announces Signing of Option Agreement for the Acquisition of a Commercial Stage Diagnostics Company, G3 Vision Labs
BERKELEY, Calif., July 31, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of an Option Agreem...
Profusa to acquire diagnostics company, appoints Jack Stover CEO
Profusa (PFSA)signed a non-binding term sheet with a privately held, commercial-stage health diagnostics and toxicology testing company – the “Dx Company -. Following the contemplated transaction, the...
Profusa Announces Key Management Changes and Signing of Non-Binding Term Sheet for the Acquisition of a Commercial Stage Diagnostics Company
BERKELEY, Calif., July 27, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces the signing of a non-binding t...
Profusa Inc trading halted, news pending
19:50 EDT Profusa (PFSA)Inc trading halted, news pending
Profusa announces 1-for-25 reverse stock split
Profusa (PFSA)filed an amendment to its amended and restated certificate of incorporation with the Secretary of State of the State of Delaware to effect a one-for-twenty-five reverse stock split of…
Profusa Announces 1-for-25 Reverse Stock Split
BERKELEY, California, July 02, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (“Profusa” or the “Company”) (Nasdaq: PFSA), a commercial stage digital health company pioneering a next-generation technology pla...
Profusa Shareholders Approve Strategic Initiatives at 2026 Annual Meeting, Supporting PanOmics Acquisition, Balance Sheet Strengthening and Nasdaq Compliance Efforts
BERKELEY, Calif., June 24, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, announces that shareholders approved all ...
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform
BERKELEY, CA, June 12, 2026 (GLOBE NEWSWIRE) -- Profusa, Inc. (Nasdaq: PFSA), a digital health company pioneering next-generation biosensing technologies, today announces that it has submitted its res...